Kwang Jin Chun1, Kyeongmin Byeon1, Sung Il Im1, Kyoung-Min Park1, Seung-Jung Park1, June Soo Kim1, Young Keun On2. 1. Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. 2. Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Electronic address: yk.on@samsung.com.
Abstract
PURPOSE: Our objective was to compare the efficacy of dronedarone and propafenone in maintaining sinus rhythm in patients with atrial fibrillation (AF) after electrical cardioversion. METHODS: In this single-center, open-label, randomized trial, we randomly assigned patients with AF after electrical cardioversion to receive dronedarone 400 mg BID or propafenone 150 mg TID. Follow-up clinical evaluations were conducted at 1, 2, 3, and 6 months of treatment. The primary end point was the time to the first recurrence of AF. FINDINGS: A total of 98 patients were enrolled (79 men; mean age, 59.2 years; n = 49 per group). The median times to first recurrence of AF were 31 days in the dronedarone group and 32 days in the propafenone group (P = 0.715). The median (interquartile range) ventricular rates at first recurrence of AF were 76.5 (67.3-86.5) beats/min in the dronedarone group and 83.0 (71.0-96.0) beats/min in the propafenone group (P = 0.059). IMPLICATIONS: Dronedarone and propafenone had similar efficacies in maintaining sinus rhythm in patients with AF after electrical cardioversion. The ventricular rate at the first recurrence of AF was numerically but not statistically significantly lower in the dronedarone group than in the propafenone group. ClinicalTrials.gov identifier: NCT01991119.
RCT Entities:
PURPOSE: Our objective was to compare the efficacy of dronedarone and propafenone in maintaining sinus rhythm in patients with atrial fibrillation (AF) after electrical cardioversion. METHODS: In this single-center, open-label, randomized trial, we randomly assigned patients with AF after electrical cardioversion to receive dronedarone 400 mg BID or propafenone 150 mg TID. Follow-up clinical evaluations were conducted at 1, 2, 3, and 6 months of treatment. The primary end point was the time to the first recurrence of AF. FINDINGS: A total of 98 patients were enrolled (79 men; mean age, 59.2 years; n = 49 per group). The median times to first recurrence of AF were 31 days in the dronedarone group and 32 days in the propafenone group (P = 0.715). The median (interquartile range) ventricular rates at first recurrence of AF were 76.5 (67.3-86.5) beats/min in the dronedarone group and 83.0 (71.0-96.0) beats/min in the propafenone group (P = 0.059). IMPLICATIONS: Dronedarone and propafenone had similar efficacies in maintaining sinus rhythm in patients with AF after electrical cardioversion. The ventricular rate at the first recurrence of AF was numerically but not statistically significantly lower in the dronedarone group than in the propafenone group. ClinicalTrials.gov identifier: NCT01991119.
Authors: Hye Bin Gwag; Kwang Jin Chun; Jin Kyung Hwang; Seung-Jung Park; June Soo Kim; Kyoung-Min Park; Young Keun On Journal: PLoS One Date: 2018-05-22 Impact factor: 3.240
Authors: Boyoung Joung; Jung Myung Lee; Ki Hong Lee; Tae Hoon Kim; Eue Keun Choi; Woo Hyun Lim; Ki Woon Kang; Jaemin Shim; Hong Euy Lim; Junbeom Park; So Ryoung Lee; Young Soo Lee; Jin Bae Kim Journal: Korean Circ J Date: 2018-12 Impact factor: 3.243
Authors: Artak Khachatryan; Jose L Merino; Francisco Jose de Abajo; Giovanni L Botto; Paulus Kirchhof; Guenter Breithardt; Bruce Stambler; Lucien Abenhaim; Lamiae Grimaldi-Bensouda Journal: Europace Date: 2022-07-15 Impact factor: 5.486